Trial Profile

Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 05 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Spartalizumab (Primary)
Indications Advanced breast cancer; Carcinoma; Malignant melanoma; Non-small cell lung cancer; Solid tumours; Thyroid cancer
Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
Sponsors Novartis Pharmaceuticals

Most Recent Events

04 Aug 2020 Status changed from active, no longer recruiting to completed.
02 Aug 2020 This trial has been completed in Hungary, according to European Clinical Trials Database. (2020-07-21)
04 May 2020 Results published in the Journal of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com